Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult XXXX .

@entity1 @entity20145 @entity5310 @entity272
BACKGROUND: @entity272 are the predominant clinical feature of the commonest form of @entity5310 . @entity5310 is classified according to World Health Organization criteria. Determination of the levels of mast-cell mediators or their metabolites reflects the mast-cell burden. The extent of @entity20145 can be assessed clinically using a scoring system (SCORing MAstocytosis; SCORMA Index) that we have developed. OBJECTIVE: Serum tryptase levels were compared with the SCORMA Index in a large group of paediatric and adult @entity1 to investigate whether there was any correlation between the two. METHODS: The SCORMA Index in 64 @entity1 (31 @entity1 and 33 adults) was compared with serum tryptase levels. The results of the first visit at which SCORMA and tryptase were evaluated were analysed. RESULTS: There was a positive correlation between the SCORMA Index and serum tryptase levels, indicating the value of the SCORMA Index in the assessment of @entity5310 with @entity272 . CONCLUSION: The results of this study showed that the SCORMA Index is a useful tool for evaluating the severity of @entity20145 . The correlation between the SCORMA Index and serum tryptase levels underlines the benefit of the SCORMA Index as a clinical tool. Repeated SCORMA Index measurements can provide a rapid impression of changes in the clinical state of @entity5310 . This is particularly relevant in @entity1 , because taking blood samples from this group is much more difficult. The well-established methods for evaluation of disease severity may be expanded by the rapid SCORMA Index method.
